Erratum

This article refers to:

Trends and geographical variation in invasive pneumococcal infections in Finland

Klemets P, Lyytikäinen O, Ruutu P, Kaijalainen T, Leinonen M, Ollgren J, Nuorti JP Trends and geographical variation in invasive pneumococcal infections in Finland. Scand J Infect Dis 2008;40:621 – 8. In the article, the proportion of pneumococcal isolates belonging to serotypes included in the 10-valent conjugate vaccine was miscalculated. The correct proportion among children aged <5 is to be 75.9%. Please see below for the revised Table IIIa and Table IIIb.

Table IIIa. The most common serotypes of S. pneumoniae in invasive infections among children, Finland, 1995 – 2002.

	Number of isolates among children (%)
Individual serotype^a	<1 y	1 y	2–4 y	5–17 y	Total
6B	22 (15.2)	56 (23.0)	36 (19.5)	10 (6.2)	124 (16.9)
14	18 (12.4)	59 (24.3)	31 (16.8)	10 (6.2)	118 (16.1)
19A	21 (14.5)	18 (7.4)	15 (8.1)	4 (2.5)	58 (7.9)
18C	7 (4.8)	17 (7.0)	17 (9.2)	16 (9.9)	57 (7.8)
7F	14 (9.7)	9 (3.7)	8 (4.3)	25 (15.5)	56 (7.6)
23F	12 (8.3)	18 (7.4)	12 (6.5)	13 (8.1)	55 (7.5)
19F	11 (7.6)	20 (8.2)	15 (8.1)	8 (5.0)	54 (7.4)
4	6 (4.1)	8 (3.3)	14 (7.6)	19 (11.8)	47 (6.4)
6A	7 (4.8)	10 (4.1)	11 (5.9)	6 (3.7)	34 (4.6)
9V	7 (4.8)	7 (2.9)	7 (3.8)	11 (6.8)	32 (4.4)
Other serotypes/groups	20 (13.8)	21 (8.6)	19 (10.3)	39 (24.2)	99 (13.5)
All serotypes	145 (19.8)	243 (33.1)	185 (25.2)	161 (21.9)	734 (18.1)
Serotypes included in vaccines
7-valent	83 (57.2)	185 (76.1)	132 (71.3)	87 (54.0)	487 (66.3)
10-valent	97 (66.9)	194 (79.8)	144 (77.8)	121 (75.2)	556 (75.7)
13-valent	127 (87.6)	225 (92.6)	171 (92.4)	135 (83.9)	658 (89.6)

^aAll serotypes constituting at least 2% of all cases are listed individually.

Table IIIb. The most common serotypes of S. pneumoniae in invasive infections among adults, Finland, 1995 – 2002.

	Number of isolates (%) among adults
Individual serotype^a	18–34 y	35–49 y	50–64 y	65–74 y	≥ 75 y	Total
4	90 (22.9)	140 (18.3)	120 (13.7)	77 (12.8)	66 (9.6)	493 (14.8)
14	42 (10.7)	73 (9.5)	106 (12.1)	60 (10.0)	94 (13.6)	375 (11.3)
3	14 (3.6)	90 (11.7)	94 (10.8)	70 (11.6)	62 (9.0)	330 (9.9)
7F	75 (19.1)	72 (9.4)	62 (7.1)	37 (6.2)	34 (4.9)	280 (8.4)
23F	21 (5.3)	29 (3.8)	56 (6.4)	52 (8.7)	68 (9.9)	226 (6.8)
9V	34 (8.7)	54 (7.0)	44 (5.0)	29 (4.8)	30 (4.4)	191 (5.7)
6B	8 (2.0)	22 (2.9)	39 (4.5)	26 (4.3)	47 (6.8)	142 (4.3)
19F	6 (1.5)	13 (1.7)	29 (3.3)	35 (5.8)	47 (6.8)	130 (3.9)
22F	15 (3.8)	24 (3.1)	39 (4.5)	18 (3.0)	33 (4.8)	129 (3.9)
6A	4 (1.0)	15 (2.0)	34 (3.9)	21 (3.5)	34 (4.9)	108 (3.3)
9N	8 (2.0)	20 (2.6)	35 (4.0)	16 (2.7)	24 (3.5)	103 (3.1)
8	9 (2.3)	39 (5.1)	24 (2.7)	14 (2.3)	9 (1.3)	95 (2.9)
19A	10 (2.5)	13 (1.7)	18 (2.1)	25 (4.2)	26 (3.8)	92 (2.8)
18C	9 (2.3)	17 (2.2)	27 (3.1)	16 (2.7)	18 (2.6)	87 (2.6)
Other serotypes/groups	48 (12.2)	145 (18.9)	146 (16.7)	105 (17.5)	97 (14.1)	541 (16.3)
All serotypes	393 (11.8)	766 (23.1)	873 (26.3)	601 (18.1)	689 (20.7)	3322 (81.9)
Serotypes included in vaccines
7-valent	210 (53.4)	348 (45.4)	421 (48.2)	295 (49.1)	370 (53.7)	1644 (49.5)
10-valent	298 (75.8)	439 (57.3)	490 (56.1)	336 (55.9)	405 (58.8)	1968 (59.2)
13-valent	326 (83.0)	557 (72.7)	636 (72.9)	452 (75.2)	527 (76.5)	2498 (75.2)
23-valent^b	370 (94.1)	675 (88.1)	761 (87.2)	512 (85.2)	598 (86.8)	2916 (87.8)
23-valent^c	359 (91.3)	636 (83.0)	707 (81.0)	485 (80.7)	565 (82.0)	2752 (82.8)

^a All serotypes constituting at least 2% of all cases are listed individually.

^b All serogroups included in the PPV23 vaccine.

^c Excluding serogroups 10, 11, 12, 15, 17, and 33, none of which was serotyped.